Wintrust Investments LLC Acquires 900 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Wintrust Investments LLC increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 86.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,937 shares of the biopharmaceutical company's stock after buying an additional 900 shares during the quarter. Wintrust Investments LLC's holdings in Madrigal Pharmaceuticals were worth $597,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MDGL. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth about $70,000. Quest Partners LLC raised its holdings in Madrigal Pharmaceuticals by 172.8% during the 3rd quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company's stock worth $123,000 after buying an additional 368 shares during the period. KBC Group NV lifted its stake in Madrigal Pharmaceuticals by 73.5% in the fourth quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company's stock valued at $188,000 after buying an additional 258 shares in the last quarter. Miracle Mile Advisors LLC acquired a new position in shares of Madrigal Pharmaceuticals in the fourth quarter valued at approximately $216,000. Finally, D.A. Davidson & CO. acquired a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth $221,000. 98.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MDGL has been the subject of a number of research analyst reports. HC Wainwright upped their target price on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. JMP Securities reiterated a "market outperform" rating and set a $427.00 price objective on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. B. Riley upgraded Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and boosted their target price for the company from $236.00 to $422.00 in a research note on Thursday, February 27th. Citigroup raised their price target on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $378.44.

Remove Ads

Insider Buying and Selling

In related news, Director James M. Daly sold 15,470 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $347.45, for a total value of $5,375,051.50. Following the completion of the transaction, the director now owns 1,912 shares of the company's stock, valued at $664,324.40. The trade was a 89.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Robert E. Waltermire sold 14,113 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $341.32, for a total transaction of $4,817,049.16. Following the completion of the transaction, the vice president now owns 3,728 shares of the company's stock, valued at $1,272,440.96. The trade was a 79.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,900 shares of company stock valued at $12,168,079. 22.80% of the stock is owned by company insiders.

Madrigal Pharmaceuticals Stock Performance

Madrigal Pharmaceuticals stock traded down $5.91 during mid-day trading on Monday, hitting $342.44. 291,826 shares of the company's stock traded hands, compared to its average volume of 397,116. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $189.00 and a fifty-two week high of $377.46. The stock has a market cap of $7.56 billion, a price-to-earnings ratio of -13.65 and a beta of -0.41. The firm has a 50 day simple moving average of $326.55 and a two-hundred day simple moving average of $290.78. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) EPS for the quarter, topping the consensus estimate of ($4.32) by $1.61. The company had revenue of $103.32 million for the quarter, compared to the consensus estimate of $97.81 million. On average, research analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.